Press Releases May 11, 2026 10:57 AM

Progyny, Inc. to Present at BofA Securities 2026 Health Care Conference

Progyny Executives to Present at BofA Securities 2026 Health Care Conference

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
PGNY

Progyny, Inc., a leader in women's health and family building solutions, announced that its CEO and CFO will participate in a fireside chat at the BofA Securities 2026 Health Care Conference. The event will be livestreamed and provide insights into the company's developments and strategy.

Progyny, Inc. to Present at BofA Securities 2026 Health Care Conference
PGNY
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Progyny provides comprehensive women's health and fertility benefits solutions aimed at improving clinical outcomes and reducing healthcare costs.
  • The company is recognized for its growth and leadership, earning several industry accolades including TIME100 Most Influential Company and CNBC Disruptor 50.
  • Presentation at the conference offers an opportunity to update investors and stakeholders on the company’s progress and market strategy.

NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, today announced that Progyny’s Chief Executive Officer, Pete Anevski, and Chief Financial Officer, Mark Livingston, will participate in a fireside chat at the BofA Securities 2026 Health Care Conference on Tuesday, May 12, 2026, at 11:20 A.M. Pacific Time / 2:20 P.M. Eastern Time.

A live audiocast and replay will be available from the Events and Presentations section of Progyny’s website at http://investors.progyny.com.

About Progyny

Progyny (Nasdaq: PGNY) is a global leader in women’s health and family building solutions, trusted by the nation’s leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive, and intentionally designed solutions simultaneously benefit employers, patients, and physicians.

Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs.

Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, Inc. 5000, Inc. Power Partners, and Crain's Fast 50 for NYC. For more information, visit www.progyny.com.

Progyny Select supplemental insurance plans are offered through subsidiaries of Progyny Inc. with state licensure to offer supplemental coverage. All insurance policies and plans contain exclusions and limitations for full details on coverage. Please refer to specific plan documents and certificates of coverage.

For Further Information, Please Contact:
Investors:
James Hart
[email protected]

Media:
Alexis Ford
[email protected]


Risks

  • Market acceptance and adoption of Progyny’s health plans could be impacted by competition and changes in employer healthcare benefit preferences.
  • Regulatory changes in healthcare and insurance markets could affect the company's business model and supplemental insurance offerings.
  • Economic or demographic shifts could influence demand for fertility and women's health services, affecting revenue growth.

More from Press Releases

Space Exploration Technologies Corporation to Join the Nasdaq-100 Index® Beginning July 7, 2026 Jun 26, 2026 XMax Announces Up to Approximately US$25 million in AI API-Related Service Contracts and Expansion into GPU-as-a-Service Jun 26, 2026 Cartesian Growth Corporation IV Announces Closing of $275 Million Initial Public Offering Jun 26, 2026 dLocal added to membership of US small-cap Russell 2000® Index Jun 26, 2026 Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance Jun 26, 2026